June 2009

|
Volume 21 Issue 6
The debate continues in the cardiology community over indications of percutaneous closure of patent foramen ovale (PFO) with or without an associated atrial septal aneurysm (ASA). Observational studies with control cohorts have shown an association b…
ABSTRACT: Objective. We sought to evaluate the short- and long-term outcomes of Amplatzer Multi-Fenestrated Septal Occluder Cribriform (AMF) device use in the percutaneous closure of patent foramen ovale (PFO) associated with atrial septal aneurysm (…
ABSTRACT: Background. An occluding device for closure of patent ductus arteriosus (PDA) was developed from meshed nitinol wires coated with platinum for prevention of nickel release after implantation. Objectives. Our purpose was to assess the immedi…
ABSTRACT: Background. The Mynx™ vascular closure device (VCD) (AccessClosure, Inc., Mountain View, California) is used for extravascular closure of the common femoral artery (CFA) after diagnostic or interventional endovascular procedures. Although i…
Peripheral arterial disease (PAD) is a common manifestation of atherosclerosis and is associated with a high risk of cardiovascular morbidity and mortality. Despite the magnitude of the problem, PAD is often poorly recognized in clinical practice. Wh…
ABSTRACT: Objective. The treatment of long superficial femoral artery (SFA) chronic total occlusions (CTOs) remains controversial. There are several percutaneous treatment options available for the recanalization of these lesions. Percutaneous transl…
ABSTRACT: Background. Gender differences that exist in patients with acute coronary disease (ACD) are unexplained. We sought to determine if these differences could be related to differences in the pathologic substrate found in the coronary arteries…
ABSTRACT: Background. Predictors of target lesion revascularization (TLR) have not been well defined in patients undergoing peripheral percutaneous interventions (PPI). In this study we analyze predictors of TLR in a consecutive cohort of patients fr…
The routine use of more potent antiplatelet and antithrombotic therapies led to substantial improvements in outcomes after percutaneous coronary intervention (PCI) and has contributed to the interventionist’s ability to treat more complex lesions in…
Frequency and Outcomes of Provisional Glycoprotein IIb/IIIa Blockade in Patients Receiving Bivalirudin during Percutaneous Coronary Intervention ABSTRACT: Objectives. This study sought to evaluate the frequency and efficacy of combination of bivali…